Ronald Glassman, MD
Ophthalmology · Teaneck, NJNPI 1316930936
Payments from drug & device makers
Across 321 payments — averaging $26.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$3K
- NEW World Medical,inc.$836
- AbbVie$799
- Sun Pharmaceutical Industries Inc.$694
- Aerie Pharmaceuticals, Inc.$681
- Dompe US, Inc.$292
- plus $2K from 19 others
What the payments were for
- Consulting fees$6007%
- Speaking & faculty fees$1,80021%
- Travel & lodging$340%
- Food & beverage$6,19372%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 94 | $3,428 |
| NEW World Medical,inc. | 7 | $836 |
| AbbVie(2 entities) | 48 | $799 |
| Sun Pharmaceutical Industries Inc. | 48 | $694 |
| Aerie Pharmaceuticals, Inc. | 11 | $681 |
| Dompe US, Inc. | 19 | $292 |
| Alcon | 19 | $255 |
| Sight Sciences, Inc. | 6 | $235 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $216 |
| Oyster Point Pharma, Inc. | 11 | $195 |
| Eyevance Pharmaceuticals LLC | 9 | $187 |
| Biotissue Holdings Inc. | 1 | $140 |
| Glaukos Corporation | 2 | $135 |
| Tarsus Pharmaceuticals, Inc. | 17 | $134 |
| Kala Pharmaceuticals, Inc. | 5 | $72 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Novartis | 5 | $63 |
| Ocular Therapeutix, Inc. | 3 | $45 |
| Lensar, Inc. | 1 | $42 |
| Shire North American Group Inc | 3 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $24 |
| Amgen | 1 | $17 |
| Harrow Eye, LLC | 1 | $17 |
| Omeros Corporation | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$4,279
- Ahmed Glaucoma Valve$619
- Kahook Dual Blade$619
- Rhopressa$600
- Rocklatan$600
- Streamline Surgical System$412
- OMNI(R) SURGICAL SYSTEM (US)$144
- SION SURGICAL INSTRUMENT$144
- AmnioGraft$140
- enVista Aspire IOL$125
- iDoseTR$111
- Oxervate$108
- CEQUA$107
How this compares
$8,645 in reported general payments places this provider in the 85th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 142 | $144,785 |
| XiidraLifitegrast | 38 | $55,336 |
| LumiganBimatoprost | 121 | $53,337 |
| RocklatanNetarsudil Mesylat/Latanoprost | 72 | $41,353 |
| XdemvyLotilaner | 19 | $34,067 |
| Cyclosporine | 44 | $29,807 |
| MieboPerfluorohexyloctane/Pf | 26 | $27,817 |
| VyzultaLatanoprostene Bunod | 69 | $25,919 |
| CequaCyclosporine | 26 | $21,802 |
| ProlensaBromfenac Sodium | 55 | $18,533 |
| TyrvayaVarenicline Tartrate | 24 | $17,298 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $13,572 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $13,123 |
| RhopressaNetarsudil Mesylate | 25 | $8,849 |
| Prednisolone Acetate | 178 | $7,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $799 | $211,244295 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $3,428 | $109,072133 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $681 | $50,20197 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $134 | $34,06719 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $694 | $21,80226 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $24 | $21,15474 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $195 | $17,29824 claims |
| AlconSimbrinza | $255 | $13,57239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Teaneck
- Luis Gonzalez GonzalezTeaneck$727K
- Peter HershTeaneck$249K
- Steven GreensteinTeaneck$53K
- Tamara LenisTeaneck$12K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.